openPR Logo
Press release

Chronic Kidney Disease FDA Approvals, Emerging Drugs, and Pipeline 2024 | Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics

07-16-2024 11:14 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Chronic Kidney Disease Pipeline

Chronic Kidney Disease Pipeline

DelveInsight's, "Chronic Kidney Disease Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Chronic Kidney Disease Treatment Drugs @ Chronic Kidney Disease Pipeline Outlook- https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Kidney Disease Pipeline Report
• July 2024:- AstraZeneca- The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effect of the balcinrenone/dapagliflozin on urinary albumin-to-creatinine ratio (UACR), compared with dapagliflozin in patients with CKD. This is a dose-finding study aiming to identify an optimal dose of balcinrenone/dapagliflozin for a future Phase III study in patients with CKD.
• July 2024:- Mineralys Therapeutics Inc.- The study consists of up to a 2-week Screening period, a 2-week run-in period where subjects will either begin study provided dapagliflozin 10 mg or continue on their regularly prescribed SGLT2i, and two DB 4-week treatment periods separated by a 4-week washout period. Subjects will be randomized (1:1) to two treatment sequences: lorundrostat-placebo (LP) and placebo-lorundrostat (PL).
• DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
• The leading companies working in the Chronic Kidney Disease market include Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies, Inc., MISSION Therapeutics, AceLink Therapeutics, and others.
• Promising Chronic Kidney Disease Pipeline Therapies in the various stages of development roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

Stay ahead with the most recent pipeline outlook for Chronic Kidney Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chronic Kidney Disease Approved Drugs- https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Kidney Disease Emerging Drugs Profile
• Baxdrostat: AstraZeneca
• Semaglutide: Novo Nordisk
• BI-685509: Boehringer Ingelheim
• Tirzepatide: Eli Lilly and Company
• CLBS201: Lisata Therapeutics
• RGLS8429: Regulus Therapeutics

Chronic Kidney Disease Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the therapies for Chronic Kidney Disease. The companies which have their Chronic Kidney Disease drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca and Novo Nordisk.

Explore groundbreaking therapies and clinical trials in the Chronic Kidney Disease Pipeline. Access DelveInsight's detailed report now! @ Chronic Kidney Disease Treatment Drugs- https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chronic Kidney Disease Pipeline Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Chronic Kidney Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Kidney Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Kidney Disease Pipeline Report
• Coverage- Global
• Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Chronic Kidney Disease Companies- Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies, Inc., MISSION Therapeutics, AceLink Therapeutics, and others.
• Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

Get the latest on Chronic Kidney Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Kidney Disease Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Chronic Kidney Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Kidney Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. KBP-5074: KBP Biosciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. DM199: DiaMedica Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AL-01211: AceLink Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. SCO-116: Scohia Pharma
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Kidney Disease Key Companies
21. Chronic Kidney Disease Key Products
22. Chronic Kidney Disease- Unmet Needs
23. Chronic Kidney Disease- Market Drivers and Barriers
24. Chronic Kidney Disease- Future Perspectives and Conclusion
25. Chronic Kidney Disease Analyst Views
26. Chronic Kidney Disease Key Companies
27. Appendix

For further information on the Chronic Kidney Disease Pipeline therapeutics, reach out to Chronic Kidney Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Top Selling Market Research Reports in 2024

Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Chronic Neuropathic Pain Market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Hydrocephalus Treatment Market- https://www.delveinsight.com/report-store/hydrocephalus-market
Cancer Therapy Market- https://www.delveinsight.com/report-store/cancer-therapy-market
Glaucoma Market- https://www.delveinsight.com/report-store/glaucoma-market
Methicillin-resistant Staphylococcus Aureus Mrsa Infection Market- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market
Glioblastoma Multiforme Market- https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
Polycystic Ovarian Syndrome Market- https://www.delveinsight.com/report-store/polycystic-ovarian-syndrome-market
Radiodermatitis Market- https://www.delveinsight.com/report-store/radiodermatitis-market
Rhinosinusitis Market- https://www.delveinsight.com/report-store/rhinosinusitis-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Vulvar Cancer Market- https://www.delveinsight.com/report-store/vulvar-cancer-market
Wilms Tumor Market- https://www.delveinsight.com/report-store/wilms-tumor-market
Hidradenitis Suppurativa Market- https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market
Uveitis Market- https://www.delveinsight.com/report-store/uveitis-market
Venous Thromboembolism Market- https://www.delveinsight.com/report-store/venous-thromboembolism-market
Beta Thalassemia Market- https://www.delveinsight.com/report-store/beta-thalassemia-market
Cold Agglutinin Disease Market- https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-market
Postpartum Depression Market- https://www.delveinsight.com/report-store/postpartum-depression-ppd-market
Radiation Dermatitis Market- https://www.delveinsight.com/report-store/radiation-dermatitis-market
Synovial Sarcoma Market- https://www.delveinsight.com/report-store/synovial-sarcoma-market
Tendinopathy Market- https://www.delveinsight.com/report-store/tendinopathy-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Diabetic Nephropathy Market- https://www.delveinsight.com/report-store/diabetic-nephropathy-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Pcsk9 Inhibitors Market- https://www.delveinsight.com/report-store/pcsk9-inhibitors-market
Respiratory Syncytial Virus Market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
Chemotherapy Induced Neutropenia Market- https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
Glioblastoma Multiforme Market- https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
Immune Thrombocytopenia Market- https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Post Operative Pain Management Market- https://www.delveinsight.com/report-store/post-operative-pain-management-market
Primary Biliary Cholangitis Market- https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market
Progressive Supranuclear Palsy Market- https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market
Membranous Nephropathy Market- https://www.delveinsight.com/report-store/membranous-nephropathy-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Diabetic Retinopathy Market- https://www.delveinsight.com/report-store/diabetic-retinopathy-market
Post Operative Pain Market- https://www.delveinsight.com/report-store/postoperative-pain-market
Genital Herpes Market- https://www.delveinsight.com/report-store/genital-herpes-market
Axillary Hyperhidrosis Market- https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors.

Contact Us
Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Kidney Disease FDA Approvals, Emerging Drugs, and Pipeline 2024 | Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics here

News-ID: 3583180 • Views:

More Releases from DelveInsight Business Research LLP

Adrenal Crisis Market to Grow Positively at a Significant CAGR, asserts DelveInsight | Antares Pharma, Eton Pharmaceuticals, and others
Adrenal Crisis Market to Grow Positively at a Significant CAGR, asserts DelveIns …
DelveInsight's "Adrenal Crisis - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Adrenal Crisis market share of the individual therapies, current and forecasted Adrenal Crisis market size from 2020 to 2034 segmented by seven major markets. The report also offers current Adrenal Crisis therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the
Sarcopenia Market to Grow Positively at a Paltry CAGR During the Study Period (2020-2034) | Biophytis, Rejuvenate Biomed, Lipocine Inc, and others
Sarcopenia Market to Grow Positively at a Paltry CAGR During the Study Period (2 …
DelveInsight's "Sarcopenia - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Sarcopenia market share of the individual therapies, current and forecasted Sarcopenia market size from 2020 to 2034 segmented by seven major markets. The report also offers current Sarcopenia therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the
Autosomal Dominant Polycystic Kidney Disease Market to Grow Positively at a Paltry CAGR During the Study Period | Otsuka Pharmaceutical, Sanofi, Regulus Therapeutics, and others
Autosomal Dominant Polycystic Kidney Disease Market to Grow Positively at a Palt …
DelveInsight's "Autosomal Dominant Polycystic Kidney Disease - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Autosomal Dominant Polycystic Kidney Disease market share of the individual therapies, current and forecasted Autosomal Dominant Polycystic Kidney Disease market size from 2020 to 2034 segmented by seven major markets. The report also offers current Autosomal Dominant Polycystic Kidney Disease therapy algorithms, market drivers, market barriers, and unmet
Adenoid Cystic Carcinoma Market to Grow Positively at a Paltry CAGR During the Study Period (2019-2032) | Merck, Ayala Pharmaceuticals, and others
Adenoid Cystic Carcinoma Market to Grow Positively at a Paltry CAGR During the S …
DelveInsight's "Adenoid Cystic Carcinoma - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Adenoid Cystic Carcinoma market share of the individual therapies, current and forecasted Adenoid Cystic Carcinoma market size from 2019 to 2032 segmented by seven major markets. The report also offers current Adenoid Cystic Carcinoma therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the

All 5 Releases


More Releases for Disease

Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,
Autoimmune Disease Diagnostic Market By Disease, Tests Type, Regions, Companies
"The Latest Research Report Autoimmune Disease Diagnostic Market, Global Forecast, By Disease, Tests Type, Regions, Companies provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Autoimmune Disease Diagnostic Market is anticipated to exceed US$ 18 Billion, experiencing a significant growth over the forecast period. Autoimmune diseases take place when there is disruption of the usual control process (immune system of the body becomes
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and